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Granulocyte-colony stimulating factor (G-CSF) increases recovery of rodent skeletal
muscles after injury, and increases muscle function in rodent models of neuromuscular
disease. However, the mechanisms by which G-CSF mediates these effects are
poorly understood. G-CSF acts by binding to the membrane spanning G-CSFR and
activating multiple intracellular signaling pathways. Expression of the G-CSFR within the
haematopoietic system is well known, but more recently it has been demonstrated
to be expressed in other tissues. However, comprehensive characterization of G-CSFR
expression in healthy and diseased skeletal muscle, imperative before implementing
G-CSF as a therapeutic agent for skeletal muscle conditions, has been lacking. Here
we show that the G-CSFR is expressed in proliferating C2C12 myoblasts, differentiated
C2C12 myotubes, human primary skeletal muscle cell cultures and in mouse and human
skeletal muscle. In mdx mice, a model of human Duchenne muscular dystrophy (DMD),
G-CSF mRNA and protein was down-regulated in limb and diaphragm muscle, but
circulating G-CSF ligand levels were elevated. G-CSFR mRNA in the muscles of mdx
mice was up-regulated however steady-state levels of the protein were down-regulated.
We show that G-CSF does not influence C2C12 myoblast proliferation, differentiation
or phosphorylation of Akt, STAT3, and Erk1/2. Media change alone was sufficient to
elicit increases in Akt, STAT3, and Erk1/2 phosphorylation in C2C12 muscle cells and
suggest previous observations showing a G-CSF increase in phosphoprotein signaling
be viewed with caution. These results suggest that the actions of G-CSF may require
the interaction with other cytokines and growth factors in vivo, however these data
provides preliminary evidence supporting the investigation of G-CSF for the management
of muscular dystrophy.
Keywords: G-CSF, cytokine receptor, skeletal muscle, duchenne muscular dystrophy, mdx , C2C12, proliferation,
differentiation
INTRODUCTION
Skeletal muscle atrophy is a devastating condition that is char-
acteristic of neuromuscular diseases such as Duchenne muscular
dystrophy (DMD) and many chronic diseases including cancer,
heart disease, chronic obstructive pulmonary disease (COPD),
sepsis and AIDS (Jagoe and Goldberg, 2001). As a result, skeletal
muscle atrophy is a strong predictor of morbidity and mortality
associated with cardiovascular, musculoskeletal, nervous, renal,
and respiratory diseases, as well as cancer, which are among the
leading causes of death worldwide (Murray and Lopez, 1997; Dal-
Re, 2011). Therefore, development of therapeutic strategies to
reduce muscle wasting while enhancing muscle regeneration and
growth is required to improve clinical outcomes.
Granulocyte-colony stimulating factor (G-CSF, encoded by
CSF3) is a cytokine that stimulates haematopoietic stem cell
mobilization, myelopoiesis, and particularly the production and
activation of neutrophils (Roberts, 2005). G-CSF exerts its effects
by binding to the G-CSF receptor (G-CSFR, encoded by CSF3R)
on target cells. G-CSFR is highly expressed on haematopoietic
stem cells and variousmyeloid cells (Nagata and Fukunaga, 1991),
but also on other cell types including neural tissue (Yata et al.,
2007; Pitzer et al., 2008, 2010), liver stem cells (Piscaglia et al.,
2007) and cardiacmuscle (Li et al., 2006, 2007; Takano et al., 2006;
Ueda et al., 2006; Shimoji et al., 2010). These observations sug-
gest that G-CSF may regulate cells outside of the haematopoietic
system.
Skeletal muscle precursor cells, retinal muscle, and muscles of
the tongue have been shown to express G-CSFR during embry-
onic development (Kirsch et al., 2008; Oishi et al., 2008). More
recently, G-CSFR expression has been also reported on prolifer-
ating C2C12 myoblasts using immunofluorescence and Western
blotting (Hara et al., 2011). However, mRNA and protein levels of
G-CSF and the G-CSFR have not been investigated in differentiat-
ing C2C12 myoblasts, terminally differentiated C2C12 myotubes,
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primary skeletal muscle cells or mature muscle. Both G-CSF and
G-CSFR are dysregulated in many disease states. For example,
ovarian cancers express G-CSFR (Ninci et al., 2000; Savarese et al.,
2001), which contributes to cell survival and migration (Kumar
et al., 2014), and bladder cancers express G-CSFR during the early
stages of their development (Tachibana et al., 1997; Chakraborty
et al., 2004, 2006), despite these tissues not normally expressing
G-CSFR. In patients with ALS, G-CSF levels are elevated in the
cerebrospinal fluid, while G-CSFR levels are decreased (Tanaka
et al., 2006). In contrast, mouse models of ALS show increased
levels of both and G-CSF/G-CSFR in neural tissue (Pitzer et al.,
2008).
Treatment with G-CSF attenuates the severity of ischemic
heart disease, acute myocardial infarction and chronic heart fail-
ure by stimulating the proliferation of cardiomyocytes (Li et al.,
2006, 2007; Takano et al., 2006; Ueda et al., 2006). In skeletal mus-
cle, G-CSF treatment improves force recovery, activates satellite
cells and increases muscle mass following crush injury (Stratos
et al., 2007). G-CSF treatment increases muscle repair follow-
ing a local cardiotoxin (CTX) injection in mice (Naito et al.,
2009) and increases muscle function in mouse models of amy-
otrophic lateral sclerosis (ALS) (Pitzer et al., 2008). Eight weeks
of G-CSF treatment (30μg/kg/day) increased Akt phosphoryla-
tion in neural tissue of ALS mice (Pitzer et al., 2008). G-CSF
also increased Akt phosphorylation in regenerating skeletal mus-
cle after myotoxic injury (Naito et al., 2009). These observations
support a role for G-CSF in improving muscle health following
injury. Therefore, understanding the molecular mechanisms for
G-CSF action in skeletal muscle remains essential for implement-
ing G-CSF as therapeutic agent for skeletal muscle disease.
The aims of this study were to firstly, to characterize themRNA
and protein expression of G-CSF and G-CSFR during muscle cell
differentiation and in healthy and diseased mature skeletal mus-
cle. The second aim was to determine the role of G-CSF in C2C12
myoblast differentiation and its ability to phosphorylate several
proteins involved in muscle cells differentiation including Akt,
STAT3, Erk-1, and Erk-2.
METHODS
TISSUE EXTRACTIONS
The humanmuscle biopsy procedure was approved by the Deakin
University Human Research Ethics Committee in accordance
with the Declaration of Helsinki (2000). Skeletal muscle samples
were obtained under local anaesthesia (1% Xylocaine) from the
belly of the vastus lateralis muscle using a percutaneous needle
biopsy technique (Bergstrom, 1975), modified to include suction
(Evans et al., 1982). Following a small incision through the skin,
muscle biopsies were taken using a Bergstrom needle. Muscle
samples were snap frozen in liquid nitrogen for RNA and protein
extraction, with fresh muscle used for primary myoblast cultures.
The diaphragm and tibialis anterior (TA) muscles from 8 to
9 week old C57BL/10 and mdx mice were excised as part of a
previously published study (Gehrig et al., 2012). Whole blood
was obtained by cardiac puncture and immediately centrifuged
at 4000 rpm for 5min, with the upper plasma phase transferred
to a sterile Eppendorf tube and frozen at −80◦C. Male mice were
used for all experiments. All experiments were approved by the
Animal Ethics Comitte (AEC), The University of Melbourne and
conducted in accordance with the Australian code of practice for
the care and use of animals for scientific purposes, as stipulated by
the National Health and Medical Research Council (Australia).
CELL CULTURE
For myoblast proliferation experiments, C2C12 myoblasts
(American Type Culture Collection, ATCC, Manassas, VA) were
seeded at a density of 50 cells per mm2 and incubated at 37◦C,
5% CO2 in growth media consisting of high glucose Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 10%
(v/v) foetal bovine serum (FBS) (Invitrogen, Carlsbad, CA). For
myotube differentiation experiments, C2C12 were seeded at a
density of 150 cells per mm2 and incubated as above. G-CSF was
used at concentrations between 0.4 and 100 ng/ml as published
previously (Ward et al., 1999).
BAF/3[G] cells, a pro-B mouse cell line stably transfected with
G-CSFR (Ward et al., 1999), were maintained at 37◦C, 5% CO2
in DMEM containing 10% (v/v) FBS and 10% (v/v) conditioned
WEHI-3B medium. HEK293T cells (ATCC) were maintained at
37◦C, 5% CO2 in high glucose DMEM supplemented with 10%
(v/v) FBS (Invitrogen). Human primary muscle cell cultures were
established as previously described in our laboratory (Wallace
et al., 2011).
Proliferation
Cells were allowed to attach overnight before being incubated
with G-CSF at the desired concentration in DMEM supplemented
with either 10% (v/v) FBS or 2% (w/v) BSA, which was replen-
ished every 24 h. After 24, 48, 72, and 96 h C2C12 myoblasts were
incubated with 0.1μg/ml 4′,6-Diamidino-2-phenylindole dihy-
drochloride (DAPI) (Sigma-Aldrich, Castle Hill, NSW, Australia)
for 10min at room temperature. Images were obtained using
the Olympus Fluoview FV10i confocal laser scanning microscope
with dedicated software at a 10 x magnification. A minimum
of ten images per group were analyzed using ImageJ Software
(National Institutes of Health, Bethesda, MA) to quantify the
number of nuclei per image.
Myoblasts were assayed for DNA synthesis using a 5-bromo-
2′-deoxyuridine (BrdU) Labeling and Detection Kit III (Roche,
Castle Hill, NSW, Australia) according to the manufacturer’s pro-
tocol. Briefly, following 24 and 48 h of BrdU labeling (10μM),
myoblasts were fixed in 70% ethanol in 0.5M HCl at −20◦C for
30min. Following a series of PBS washes containing 10% FBS,
cells were incubated with the supplied nucleases at 37◦C in the
absence of CO2 for 30min. Cells were again washed and incu-
bated with anti-BrdU-POD Fab fragments for 30min at 37◦C.
After a final series of washes, peroxidase substrate with substrate
enhancer was added to the wells and the substrate left to develop
in the dark for 5min before the absorbance was determined at a
wavelength of 405 nm.
Differentiation
When myoblasts were confluent, DMEM containing 2%
HS ± G-CSF was added to induce differentiation. Images were
obtained every 24 h for 4 days using an Olympus IX70 micro-
scope (Olympus, Mt Waverly, VIC, Australia), and an attached
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DS-U3 microscope camera with NIS-Elements imaging software
(Nikon Instruments Inc., Melville, NY) to assess differentiation.
At the same time points RNA was extracted from the cells and
RT-PCR was performed on genetic markers of differentiation.
The media ± G-CSF was replenished every 24 h throughout the
experiment.
RNA EXTRACTION, REVERSE TRANSCRIPTION AND REAL TIME
POLYMERASE CHAIN REACTION (REAL-TIME PCR)
TRI-Reagent (Ambion Inc., Austin TX) was used to extract RNA
from each cell culture sample or approximately 20–40mg wet
weight of muscle, with RNA concentrations determined using
a NanoDrop® ND-1000 spectrophotometer (NanoDrop prod-
ucts, Wilmington, DE). The RNA was reverse transcribed (RT) to
synthesize first strand cDNA using a high-capacity RNA-cDNA
reverse transcription kit (Applied Biosystems, Foster City, CA).
Each sample was incubated with one unit of ribonuclease H
(RNAse H) (Invitrogen) at 37◦C for 30min following reverse
transcription.
A mixture containing 0.5 × SYBR® Green PCR Master Mix
(Applied Biosystems) and the forward and reverse primers for the
gene of interest (Table 1) was added to 25 ng cDNA. Real-time
polymerase chain reaction (Real-Time PCR was performed using
a Stratagene Mx3000p QPCR System (Stratagene, La, CA) run
by MxPro QPCR Software (Stratagene). All primers were used at
300 nM with an annealing temperature of 60◦C.
In some experiments, the resulting PCR products were sepa-
rated on a 1.8% agarose gel containing 0.5 × SYBR® Safe DNA
Gel Stain (Invitrogen). Images were captured using the Kodak
Gel Logic 112 image station (Kodak Scientific Imaging Systems,
Rochester, NY) under 302 nm UV light. The cDNA fragments
were purified using the QIAquick Gel Extraction Kit (QIAGEN,
Clifton Hill, VIC, Australia) according to the manufacturer’s pro-
tocol. The purified cDNA from BAF/3[G] and C2C12 myoblasts
and C2C12 myotubes was sequenced by the Australian Genome
Research Facility (AGRF, Parkville, VIC, Australia).
PROTEIN EXTRACTION ANDWESTERN BLOT ANALYSIS
Myoblasts and myotubes were serum starved in DMEM
(Invitrogen) for 4 h followed by stimulation with serum free
media ± G-CSF. Total protein was extracted after 5, 10, 15, 30,
and 90min and phosphorylation was compared to basal levels
following 4 h of serum starvation.
Total protein was extracted from muscle tissue and cell culture
using 1x radioimmunoprecipitation (RIPA) buffer (Millipore,
North Ryde, NSW) with 1μL/mL protease inhibitor cock-
tail (Sigma-Aldrich, Castle Hill, NSW) and 10μL/mL Halt
Phosphatase Inhibitor Single-Use Cocktail (Thermo Scientific,
Rockford, IL). Samples were centrifuged at 13,000 rpm for 15min
with the protein concentration of the supernatant determined
from the development of a standard curve using the bicinchoninic
acid (BCA) assay Protein Assay Kit (Pierce Biotechnology,
Rockford, IL) according to the manufacturer’s protocol.
Protein deglycosylation was performed using the PNGase F
(New England Biolabs, Ipswich, MA) according to the manufac-
turer’s protocol. In brief, 20μg total protein was denatured in 1×
glycoprotein denaturing buffer at 100◦C for 10min. Following
denaturing 1×G7 reaction buffer, 2μl 10% (v/v) NP-40 and 2μl
PNGase F was added to the protein sample. The sample was incu-
bated using a water bath at 37◦C for 1 h. The samples were frozen
at −80◦C for Western blot analysis.
Electrophoresis was performed using a 4–12% NuPAGE®
Novex Bis-Tris Gel in NuPAGE® SDS MOPS Running Buffer
(Invitrogen). Proteins were transferred to a PVDF mem-
brane (Millipore) in a Bjerrum buffer containing 50mM
Tris, 17mM glycine and 10% (v/v) methanol. The mem-
branes were blocked with 5% BSA in PBS, after which they
were incubated overnight at 4◦C with anti-G-CSFR antibody
(1:1000) (Santa Cruz Biotechnology, USA), anti-phospho-Akt
(Ser473), anti-phospho-STAT3 (Tyr705), anti-phospho-Erk1/2
(Thr202/Tyr204), anti-Akt, anti-STAT3 and and anti-Erk1/2 (Cell
Signaling Technology, Denvers, MA) diluted in PBS containing
5% BSA. Following washing, the membranes were incubated with
goat anti-rabbit IgG antibody (1:5000) labeled with an infrared-
fluorescent 800 nm dye (Alexa Fluor® 800, Invitrogen) in PBS
containing 50% Odyssey ® blocking buffer (LI-COR Biosciences,
Lincoln, USA) and 0.01% (w/v) SDS. After washing, the pro-
teins were exposed on an Odyssey ® Infrared Imaging System
(LI-COR). Anti-GAPDH antibody (1:5000) (G8795, Sigma-
Aldrich, Australia) and rabbit anti-mouse IgG antibody labeled
with an infrared-fluorescent 680 nm dye (Alexa Fluor® 680,
Invitrogen) was used as a loading control.
CYTOKINE ANALYSIS
A Milliplex assay (Millipore) was used to analyse G-CSF protein
expression in the skeletal muscle and plasma samples following
the manufacturer’s protocol (Millipore). Briefly, the samples and
Table 1 | Human and mouse PCR primer sequences.
Primer Accession no. Sense (5′–3′) Anti-sense (5′–3′)
CSF3 (G-CSF) NM_000759 GAGTTGGGTCCCACCTTG TGGAAAGCAGAGGCGAAG
CSF3R (G-CSFR) NM_000760 CCTGCATCATCAAGCAGAAC AGTTCAGGAAGCAGGAGAGA
Csf3 (G-CSF) NM_009971 CGTTCCCCTGGTCAGTGTC CCGCTGGCCTGGATCTTC
Csf3r (G-CSFR) NM_007782 TCATGGCCACCAGTCGAGC CACGCTGGAGTCCCAGAAG
Myh7 NM_080728 ACCCTCAGGTGGCTCCGAGA TGCAGCCCCAAATGCAGCCA
Myh2 NM_001039545 GAGCAAAGATGCAGGGAAAG TAAGGGTTGACGGTGACACA
Myh4 NM_010855 ACAGACTAAAGTGAAAGCC CTCTCAACAGAAAGATGGAT
Myh1 NM_030679 GGACCCACGGTCGAAGTTGCA GGAACTCATGGCTGCGGGCT
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standards were added to a 96 well plate containing premixed
beads coated with G-CSF antibody. Following a 30min incu-
bation plates were washed three times then incubated with
pre-mixed detection antibodies. Wells were then washed and
incubated with streptavidin-phycoerythrin. After a final series
of washes samples were resuspended in 125μl of assay buffer.
The plate was read on the Bio-Plex Suspension Array System
(V.5.0, Bio-Rad). For skeletal muscle, samples were extracted
according to the protein extraction method described above
and diluted to 1000μg/ml prior to the assay. Plasma sam-
ples were run undiluted. Intra-assay coefficient of variation
(CV%) was 4.2% for the plasma and 7.1% for the diaphragm
homogenate.
STATISTICAL ANALYSIS
Statistical analysis was performed using GraphPad Prism 4.1
(GraphPad Software, San Diego, CA). Comparisons between wild
type control andmdx mice were made using an unpaired Student
t-test. Significance was set at p < 0.05 for all statistical tests with
data represented as mean ± SEM.
For measurements of proliferation a One-Way ANOVA was
used to determine the interaction between treatment concentra-
tion (0, 0.4, 4, 40, and 100 ng/ml G-CSF) at each time point.
For BrdU analysis a Two-Way ANOVA was used to determine
the interaction between G-CSF concentration (0, 0.4, 4, 40,
and 100 ng/ml G-CSF) and treatment group (under normal
growth conditions vs. serum depletion). Newman-Keuls Multiple
Comparison Test was used to determine differences between
groups with significance set at p < 0.05.
For measurements of differentiation a One-Way ANOVA was
used to determine the interactions of time (day 1, 2, 3, and 4).
Furthermore, a One-Way ANOVA was used to determine the
interaction between treatment concentrations (0, 0.4, 4, 40,
and 100 ng/ml G-CSF) at each day. Newman-Keuls Multiple
Comparison Test was used to determine differences between
groups with significance set at p < 0.05.
For densitometry analysis a One-Way ANOVA was used to
determine the interaction of time (0, 5, 10, 15, 30, 60, and 90min)
at the given concentration of G-CSF treatment. Furthermore, a
Two-Way ANOVA was used to determine an interaction between
time (0, 5, and 15min) and treatment (Control and G-CSF).
Newman-Keuls Multiple Comparison Test was used to determine
differences between groups with significance set at p < 0.05.
RESULTS
IDENTIFICATION OF G-CSFR IN SKELETAL MUSCLE
To investigate the expression of the genes encoding G-CSF and G-
CSFR, intron-spanning primers described in Table 1 were used
for Real-Time PCR. Fragments of the expected ∼200 base pairs
were observed in both mouse and human myoblasts, myotubes
and tissue homogenates (Figure 1A). Sequencing of these prod-
ucts confirmed that they represented bone fide sequences, con-
firming expression of the G-CSFR in myoblasts and myotubes
(Table S1).
FIGURE 1 | Identification of G-CSFR in rodent and human skeletal
muscle. (A) cDNA fragment amplified during Real Time-PCR using the
primers described in Table 1, separated on a 1.8% Sybr safe (Invitrogen)
agarose gel and exposed to UV light. (B) Western blot image identifying
G-CSFR in rodent and human skeletal muscle in vitro and ex vivo. (C)Western
blot for G-CSFR in positive (BAF/3[G]) and negative (293T) control cells.
(D) G-CSFR after deglycosylation with PGNase. C2B (C2C12 myoblasts), C2T
(C2C12 myotubes), Dia (diaphragm muscle from C57BL/10 mice), TA (tibialis
anterior muscle from C57BL/10 mice), HpB (human primary myoblasts), HpT
(human primary myotubes) HVL (human vastus lateralis muscle), BAF/3[G]
(murine pro B cell line overexpressing G-CSFR) and 293T (human embryonic
kidney 293T cell line). Experiments were performed in triplicate.
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Using a polyclonal antibody raised against amino acids 25–200
of human G-CSFR (Santa Cruz, Delaware, CA), Western blot
analysis confirmed expression of G-CSFR protein in mouse
C2C12 and human primary myoblasts and myotubes, as well
as in mouse and human skeletal muscle (Figure 1B). Multiple
bands were observed, consistent with multiple glycosylated forms
of the receptor. Similar forms were observed in BAF/3 cells sta-
bly expressing the G-CSFR protein used as a positive control
(Figures 1B,C), but not in HEK293T cells used as a negative con-
trol since they are known not to express G-CSFR (Debruin et al.,
2010) (Figure 1C). Treatment of protein lysates with PGNase
reduced the band intensity at 110 kDa in C2C12myoblasts, C2C12
myotubes and inmouse and human skeletal muscle homogenates,
confirming the 110 kDa band as a glycosylated form of the
G-CSFR protein (Figure 1D).
To investigate the expression of the G-CSFR through-
out myotube development, differentiation of confluent C2C12
myoblasts was induced by serum depletion. C2C12 cells formed
visible myotubes after 4 days (Figure 2A), with differentiation
confirmed by measuring various myosin heavy chain (Myh7,
4, 2, 1) mRNA levels, known markers of muscle cell differ-
entiation (Brown et al., 2012). All Myh mRNAs were elevated
by day 3 (p < 0.01) and day 4 (p < 0.001) when compared to
day 0 (Figure 2B). G-CSF mRNA transiently increased by 20%
FIGURE 2 | Characterization of G-CSF and G-CSFR during C2C12
myogenesis. (A) Representative images of C2C12 during differentiation.
(B) Expression of myosin heavy chain genes (Myh7, 2, 4, 1) during following
differentiation of C2C12 cultures. (C) G-CSF (Csf3) and G-CSFR (Csf3r) mRNA
expression and (D) G-CSFR protein expression during differentiation of C2C12
cultures. Day 0 represents near confluent myoblasts (>90% confluent). Day
1 represents 24 h post serum withdrawal. mRNA is expressed as a fold
change after Day 0 (n = 3). ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001.
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(p < 0.05) at day 2 (Figure 2C), but no change in G-CSFR
mRNA or protein levels was observed during differentiation
(Figures 2C, D).
THE REGULATION OF G-CSF AND G-CSFR IN MUSCLES FROM mdx mice
Wenext sought to examine whether the expression of G-CSF or its
receptor were altered in dystrophic muscle, for which we used the
mdx mouse. G-CSF mRNA was reduced by approximately 70%
in the TA (p < 0.001) and approximately 80% in the diaphragm
muscles (p < 0.001) of 8–9 week old mdx mice compared to
littermate controls (Figures 3A,B). In contrast G-CSFR mRNA
levels were 8-fold (p < 0.01) and >15-fold (p < 0.001) higher in
the TA and diaphragm muscles, respectively, of mdx mice com-
pared with control mice (Figures 3C,D). Circulating G-CSF levels
were also significantly elevated in mdx mice compared with lit-
termate controls (p < 0.05) (Figure 4A). However, the G-CSF
protein was also reduced in the diaphragm muscle (p < 0.001)
(Figure 4B), consistent with the G-CSF mRNA analysis. Levels of
the G-CSF ligand were below the detectable limits of the assay
in the TA muscle (data not shown). In contrast to levels of the
G-CSFR mRNA, the G-CSFR protein was significantly reduced in
both the TA (p < 0.05) and diaphragmmuscle (p < 0.05) ofmdx
mice (Figures 4C,D).
THE ROLE OF G-CSF IN PROLIFERATION, DIFFERENTIATION, AND
PROTEIN SIGNALING IN C2C12 MYOBLASTS
To investigate the effects of G-CSF on myoblast proliferation,
myoblasts were enumerated by DAPI staining at 24 h inter-
vals over 96 h (Supplementary Figures 1, 2). C2C12 myoblasts
proliferated as expected, approximately doubling at 48 and 72 h,
reaching confluency and showing signs of spontaneous fusion at
96 h under normal growth conditions (Figure 5A). Slower pro-
liferation rates were observed in serum depleted conditions over
the first 48 h followed by the cessation of proliferation there-
after (Figure 5B). No changes in cell number was observed with
the addition of G-CSF up to 100 ng/ml under normal or serum
depleted conditions (Figure 5).
To confirm that G-CSF was not affecting proliferation, DNA
synthesis was assayed by BrdU incorporation in C2C12 myoblasts
for 24 and 48 h. In normal growth conditions C2C12 myoblasts
incorporated more BrdU into their cellular DNA compared to
serum depleted cells. G-CSF treatment did not have any effect on
BrdU incorporation at 24 and 48 h (Supplementary Figure 3)
To examine the effects of G-CSF on myoblast differentiation
G-CSF was added to C2C12 myoblasts during myotube for-
mation. C2C12 cells formed visible myotubes after 4 days in
the absence of G-CSF, as expected, with no visible differences
observed in G-CSF treated cells (Figure 6A). G-CSF also had no
effect on the level of expression of Myh7, Myh4, Myh2, and Myh1
which all increased during differentiation (Figures 6B–E), nor
on the myogenic regulatory factors MyoD and myogenin during
C2C12 differentiation (data not shown).
It has previously been shown that Akt and Erk1/2 phospho-
rylation were sensitive to the stress associated with changing
media in cardiomyocytes (Sinclair et al., 2010). We also exam-
ined this in C2C12 myoblasts, and observed that media changes
also led to phosphorylation of both Akt and Erk1/2 in these cells
(Figure 7). Therefore, to overcome the potential confounding
FIGURE 3 | mRNA expressions of G-CSF and G-CSFR mRNA in
muscles from mdx mice. (A) G-CSF (Csf3) mRNA in the tibialis anterior
(TA) muscle. (B) G-CSF (Csf3) mRNA in the diaphragm. (C) G-CSFR
(Csf3r) mRNA in the TA and (D) G-CSFR (Csf3r) mRNA in the diaphragm.
mRNA was normalized to cDNA content. ∗∗p < 0.01 and ∗∗∗p < 0.001
(n = 10 per group).
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FIGURE 4 | G-CSF and G-CSFR protein expression in muscles from mdx
mice. (A) Circulating plasma G-CSF levels. (B) G-CSF levels in the diaphragm
homogenate. (C) Representative western blot images for the G-CSFR in the
tibialis anterior muscle and band densitometry analysis and (D) Representative
western blot images for the G-CSFR in the diaphragm muscles from mdx
mice and littermate controls and band densitometry analysis. ∗p < 0.05 and
∗∗∗p < 0.001. Cytokine analysis (n = 10), Western Blotting (n = 8) NB: G-CSF
protein was undetectable in the TA muscle homogenate.
effect of replenishing the media we compared cells treated with
fresh media containing G-CSF (40 ng/ml) to those treated with
fresh media containing vehicle only. G-CSF did not increase Akt
or Erk1/2 phosphorylation above that of the vehicle treated cells
(Figure 8). To confirm G-CSF was not affecting intracellular sig-
naling protein in C2C12 myoblasts we used a “spike in” method
in which 20μl G-CSF was added directly to the well contain-
ing serum free media to a final concentration of 40 ng/ml. When
G-CSF was “spiked in” no changes in Akt, STAT3, or Erk1/2
phosphorylation were observed, in contrast to an insulin control
(Figure 9).
DISCUSSION
G-CSF treatment improves recovery of mouse skeletal muscle
after crush injury or myotoxic damage and improves muscle
function in mouse models of ALS (Stratos et al., 2007; Pitzer
et al., 2008; Hara et al., 2011). However, the molecular mech-
anisms responsible for this improvement in muscle function
are unknown. G-CSFR expression has been observed on vari-
ous cell types outside of the haematopoietic system leading to
speculation that G-CSFR may be expressed in skeletal muscle.
Consequently, G-CSF may directly bind to G-CSFR activat-
ing intramuscular signaling pathways involved in tissue repair.
Therefore, the present study aimed to establish and characterize
G-CSF and G-CSFR expression in proliferating, differentiating
or fully differentiated C2C12 muscle cells, human primary mus-
cle cells and in mature mouse and human muscle. Since G-CSF
and G-CSFR levels are altered in various diseases (Ninci et al.,
2000; Chakraborty and Guha, 2007; Pitzer et al., 2008, 2010;
Hsu et al., 2013), the study also sought to characterize whether
G-CSF and G-CSFR expressed was perturbed in dystrophic skele-
tal muscle. Lastly, we sought to elucidate the molecular mech-
anisms by which G-CSF exerts its effects in C2C12 myotubes.
G-CSFR expression was confirmed in C2C12 myoblasts with
several novel observations. Firstly, G-CSFR mRNA and protein
was identified in mouse C2C12 and human primary myoblasts
and myotubes and in mature skeletal muscle. Secondly, G-CSF
mRNA was down-regulated in the diaphragm and TA muscles,
while protein expression was down-regulated in the diaphragm
and indeed undetectable in the TA muscles of mdx mice com-
pared with wild type mice. In contrast, the G-CSFR mRNA levels
were increased, while G-CSFR protein levels were decreased in
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FIGURE 5 | The effects of G-CSF treatment on C2C12 myoblast
proliferation. Proliferating C2C12myoblasts incubated in the presence of
the indicated concentration of G-CSF under (A) normal growth media
containing 10% fetal bovine serum or (B) serum depleted growth media
containing 2% BSA. Data represents the mean ± SEM taken from a
minimum of 10 images per sample (n = 3).
both the diaphragm and the TA muscles of mdx mice. Lastly,
G-CSF treatment of C2C12 muscle cells did not increase prolif-
eration, differentiation or intracellular activation of Akt, STAT3,
and Erk1/2.
The identification of G-CSFR outside of tissues of
haematopoietic origin has significant clinical relevance.
Identifying G-CSFR in cardiac myocytes (Harada et al., 2005)
has seen the administration of recombinant G-CSF progress
from rodent models (Li et al., 2006; Takano et al., 2006, 2007;
Ueda et al., 2006) to human clinical trials as a therapy to combat
cardiac remodeling post infarction (Takano et al., 2007). The
present study identified G-CSFR expression at both the mRNA
and protein levels in proliferating C2C12 myoblasts, as well as
in terminally differentiated C2C12 myotubes, human primary
skeletal myoblast and myotube cultures and mature skeletal
muscles from mice and humans. Our results support a recent
report that G-CSFR protein is expressed in proliferating C2C12
myoblasts (Hara et al., 2011), although there were also several
important differences with that study. We show that G-CSFR is
expressed in both myoblasts and myotubes, as well as muscle
tissue, with multiple protein bands detected between 85 kDa
and 110 kDa by Western blot. In contrast, Hara et al. detected
a single band for the G-CSFR at 110 kDa in C2C12 myoblasts
but not in differentiated myotubes (Hara et al., 2011). Moreover,
positive and negative controls known to express/not express
the G-CSFR were not used to show antibody specificity (Hara
et al., 2011). This is important, since many G-CSFR antibodies
have been proven to lack specificity in Western blotting and
immunofluorescence (Debruin et al., 2010). In support of our
data, similar multiple G-CSFR bands have been observed in
mouse bone marrow which highly expresses G-CSFR (Hermans
et al., 1998), and in our positive control, the murine pro-B cell
line overexpressing G-CSFR. In addition, expression was con-
firmed by RT-PCR followed by sequencing of the product. This
demonstrates definitively that G-CSFR is expressed in myoblasts,
as well as differentiating and terminal myotubes, suggesting that
G-CSF may have potential to aid in muscle regeneration as well
as protecting against muscle loss by acting on mature muscle
fibers.
Both G-CSF and G-CSFR are modulated in neural tissue of
several disease models characterized with muscle atrophy and
dysfunction, such as ALS patients and rodent models of ALS
and spinal cord injury (Pitzer et al., 2008, 2010; Kawabe et al.,
2011). Similar to these models, we observed perturbations in the
expression of G-CSF and G-CSFR in the muscles of mdx mice,
a widely studied model for human DMD (Schertzer et al., 2008;
Stupka et al., 2008). In mdx mice, G-CSF mRNA was reduced
in the TA muscles and diaphragm, while G-CSF protein was
reduced in the diaphragm. G-CSFR expression was increased, as
shown by mRNA. However, plasma G-CSF was raised, proba-
bly as a result of inflammation induced by the muscle damage
(Hirose et al., 2004; Paulsen et al., 2005). This can ligate with its
receptor, thereby degrading it in the lysosome and proteasome
(Irandoust et al., 2007; Kindwall-Keller et al., 2008), leading to a
decrease in G-CSFR protein. One corollary of this scenario would
be that perhaps G-CSFR is already providing protective signals
in the mdx mouse, with symptoms potentially worsened if G-
CSFR was ablated. However, the importance of these observations
remains unknown and warrants further investigation. G-CSF
treatment in ALS mice increases muscle mass, muscle func-
tion and survival (Pitzer et al., 2008). ALS mice have increased
G-CSF and G-CSFR levels in neural tissue suggesting their ele-
vation may be an attempted “survival” mechanism for damaged
neurons and for subsequent preservation of neural innervated
muscles.
The present study demonstrated that G-CSF does not stim-
ulate C2C12 myoblast proliferation in the presence or absence
of serum. Importantly, our C2C12 myoblasts doubled approxi-
mately every 24 h in serum, and exhibited a block in proliferation
without serum, consistent with other studies (Yaffe and Saxel,
1977). In contrast, in the study by Hara et al showing G-CSF
treatment increased C2C12 myoblast proliferation they observed
a reduction in myoblast cell number in the first 48 h in the control
group (Hara et al., 2011), which may indicate cell cycle arrest and
induction of differentiation (Walsh and Perlman, 1997). They also
did not clearly describe if proliferation was measured in the pres-
ence or absence of serum, nor was the level of cell confluence at
the time of treatment with G-CSF stated (Hara et al., 2011), mak-
ing their results difficult to interpret. Myosin heavy chain proteins
regulate skeletal muscle contraction and their mRNA levels are
significantly increased during myogenesis (Brown et al., 2012).
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FIGURE 6 | The effects of G-CSF treatment on expression of Myh
genes during C2C12 cell differentiation. (A) Light microscope images
of C2C12 cells at 24 h intervals during differentiation under normal
conditions and in the presence of 40 ng/ml G-CSF. (B) Myh7 (C)
Myh2 (D) Myh4, and (E) Myh1 mRNA expression during 4 days of
differentiation with 0, 0.4, 4, 40, and 100 ng/ml G-CSF. Data is
represented as mean ± SEM of the fold change compared to the Day
1 control (n = 3).
In the current study mRNA expression levels for myosin heavy
chains (Myh-7, -4, -2 and -1) continued to increase through-
out differentiation. G-CSF had no influence on the mRNA levels
of these genes at any time point nor did G-CSF influence the
myogenic regulatory factors MyoD and myogenin. This further
supports our observation that G-CSF does not increase C2C12
myoblast proliferation or differentiation.
G-CSF is known to activate Akt, STAT3, and Erk1/2 in cells
expressing the G-CSFR (Chakraborty and Tweardy, 1998; Dong
and Larner, 2000). Serum starving (3–20 h) prior to experimen-
tal treatment is used routinely to reduce basal cellular activity
(Rommel et al., 2001; Stitt et al., 2004). Following re-stimulation
with fresh media with and without G-CSF there was a signif-
icant increases in protein phosphorylation. However, there was
no difference between the vehicle control and the G-CSF treated
groups, demonstrating the media changes alone were sufficient
to produce these changes. To confirm G-CSF was not affecting
protein phosphorylation, G-CSF was spiked into the media so
that the media was not removed from the cells. This alternative
approach also revealed that G-CSF did not increase Akt, STAT3,
or Erk1/2 phosphorylation in C2C12myoblasts. Without the nec-
essary controls, the increased protein phosphorylation observed
following media change could be mistaken as an effect of G-CSF
treatment, especially given the strong rationale and prior obser-
vations (Hara et al., 2011). However, the results of the present
study show that a media change alone is sufficient to stimulate
Akt, STAT3, and Erk1/2, indicating that G-CSF does not activate
these signaling proteins in C2C12 muscle cells.
In conclusion, we show that the G-CSFR is expressed not
just in myoblasts, but also in differentiated C2C12 and human
primary myotubes and mature mouse and human muscles.
These findings suggest that the G-CSF ligand may act directly
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FIGURE 7 | The effects of changing media on Akt and Erk1/2
phosphorylation in C2C12 myoblasts. Western blot analysis using
phospho-specific and control antibodies for (A) Akt, (B) Erk-1, and (C) Erk-2
after replenishing the media. Each panel shows a representative western
blot above a graph of the fold-change, presented as mean ± SEM
compared to time zero (n = 3, ∗p < 0.05).
on skeletal muscle via its receptor. We also show that G-CSF
and the G-CSFR are reduced in the TA and diaphragm mus-
cles from mdx mice. The relevance of altered G-CSF/G-CSFR
in the muscles of mdx mice needs to be investigated to deter-
mine a causative, passive role in disease progression or whether
G-CSF/G-CSFR is actively signaling to cause reduced G-CSFR
FIGURE 8 | Akt and Erk1/2 phosphorylation with 40ng/ml G-CSF vs.
vehicle treatment in myoblasts. Fold changes in phosphorylation for
(A) Akt (B) Erk-1, and (C) Erk-2 after treatment with fresh media containing
40 ng/ml G-CSF (black bars) or vehicle control (white bars). Data is shown
as mean ± SEM compared to time zero (n = 3, ∗p < 0.05).
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FIGURE 9 | Akt, STAT3 and Erk1/2 phosphorylation with 40ng/ml
G-CSF in C2C12 myoblasts. Representative images of Akt, STAT3, and
Erk1/2 phosphorylation following stimulation with G-CSF (40 ng/ml) from 5
to 90min. 20μl G-CSF was added to the media at time 0min. Time zero
represents 4 h after serum free media was added to the cells. Ins = C2C12
myoblast treated with 100μM insulin for 15min using the spike in
technique (n = 3).
levels. However, since G-CSF treatment increases muscle recovery
in various rodent models of trauma and/or disease, a reduc-
tion in G-CSF within the muscle suggests G-CSF may be pro-
tective against damage, or that elevating intramuscular G-CSF
promote muscle regeneration. Therefore, G-CSF may have ther-
apeutic potential for managing the pathophysiology of muscular
dystrophy.
The molecular mechanisms by which G-CSF exerts its effects
remain elusive as the current study demonstrates that G-CSF
does not increase myoblast proliferation with concentrations
ranging from 0.4 to 100 ng/ml. The actions of G-CSF may there-
fore require the interaction with other cytokines and growth
factors in vivo. For example G-CSF is known to cooperate
with stem cell factor in haematopoiesis (Duarte and Franf,
2002) and IL-6 during bone marrow stem cell tumour pro-
gression (Yan et al., 2013). Alternatively, it may act directly on
other cell populations, such as immune cells to stimulate the
release of factors that are able to act directly on muscle cells.
Furthermore, we showed that G-CSF does not increase Akt,
STAT3, or Erk1/2 above that caused by replenishing media. This
highlights the importance of using rigorous controls, meaning
those studies lacking such controls should be interpreted with
caution.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
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Supplementary Figure 1 | BrDU incorporation into proliferating C2C12
myoblasts following G-CSF treatment. Proliferating C2C12 myoblasts in
Growth Media (GM) containing DMEM + 10% FBS (black bars) or
DMEM + 2% BSA (white bars) following 0, 0.4, 4, 40, and 100 ng/ml
G-CSF treatment for (1) 24 h and (2) 48 h. Data is Mean ± SEM, n = 8,
∗p < 0.05 compared to GM.
Supplementary Figure 2 | DAPI staining of proliferating C2C12 myoblast
following G-CSF stimulation grown in 10% FBS. Representative images
following DAPI staining of C2C12myoblastsfollowing 24, 48, 72, and 96 h
in DMEM + 10% FBS with the indicated concentration of G-CSF. A
minimum of 10 images were obtained per sample (n = 3).
Supplementary Figure 3 | DAPI staining of proliferating C2C12 myoblasts
following G-CSF treatment with serum depletion. Representative images
following DAPI staining of C2C12myoblastsfollowing 24, 48, 72, and 96 h
in DMEM + 2% BSA with the indicated concentration of G-CSF. A
minimum of 10 images were obtained per sample (n = 3).
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